Stool DNA testing to screen for colorectal cancer in the Medicare population: a cost-effectiveness analysis

Iris Lansdorp-Vogelaar, Karen M Kuntz, Amy B Knudsen, Janneke A Wilschut, Ann G Zauber, Marjolein van Ballegooijen

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

BACKGROUND: The Centers for Medicare & Medicaid Services considered whether to reimburse stool DNA testing for colorectal cancer screening among Medicare enrollees.

OBJECTIVE: To evaluate the conditions under which stool DNA testing could be cost-effective compared with the colorectal cancer screening tests currently reimbursed by the Centers for Medicare & Medicaid Services.

DESIGN: Comparative microsimulation modeling study using 2 independently developed models.

DATA SOURCES: Derived from literature.

TARGET POPULATION: A cohort of persons aged 65 years. A sensitivity analysis was also conducted, in which a cohort of persons aged 50 years was studied.

TIME HORIZON: Lifetime.

PERSPECTIVE: Third-party payer.

INTERVENTION: Stool DNA test every 3 or 5 years in comparison with currently recommended colorectal cancer screening strategies.

OUTCOME MEASURES: Life expectancy, lifetime costs, incremental cost-effectiveness ratios, and threshold costs.

RESULTS OF BASE-CASE ANALYSIS: Assuming a cost of $350 per test, strategies of stool DNA testing every 3 or 5 years yielded fewer life-years and higher costs than the currently recommended colorectal cancer screening strategies. Screening with the stool DNA test would be cost-effective at a per-test cost of $40 to $60 for stool DNA testing every 3 years, depending on the simulation model used. There were no levels of sensitivity and specificity for which stool DNA testing would be cost-effective at its current cost of $350 per test. Stool DNA testing every 3 years would be cost-effective at a cost of $350 per test if the relative adherence to stool DNA testing were at least 50% better than that with other screening tests.

RESULTS OF SENSITIVITY ANALYSIS: None of the results changed substantially when a cohort of persons aged 50 years was considered.

LIMITATION: No pathways other than the traditional adenoma-carcinoma sequence were modeled.

CONCLUSION: Stool DNA testing could be a cost-effective alternative for colorectal cancer screening if the cost of the test substantially decreased or if its availability would entice a large fraction of otherwise unscreened persons to receive screening.

Original languageEnglish
Pages (from-to)368-77
Number of pages10
JournalAnnals of Internal Medicine
Volume153
Issue number6
DOIs
Publication statusPublished - 21 Sep 2010

Cite this

Lansdorp-Vogelaar, Iris ; Kuntz, Karen M ; Knudsen, Amy B ; Wilschut, Janneke A ; Zauber, Ann G ; van Ballegooijen, Marjolein. / Stool DNA testing to screen for colorectal cancer in the Medicare population : a cost-effectiveness analysis. In: Annals of Internal Medicine. 2010 ; Vol. 153, No. 6. pp. 368-77.
@article{0e9ac633a2e44e7c934651d4f5a58ca7,
title = "Stool DNA testing to screen for colorectal cancer in the Medicare population: a cost-effectiveness analysis",
abstract = "BACKGROUND: The Centers for Medicare & Medicaid Services considered whether to reimburse stool DNA testing for colorectal cancer screening among Medicare enrollees.OBJECTIVE: To evaluate the conditions under which stool DNA testing could be cost-effective compared with the colorectal cancer screening tests currently reimbursed by the Centers for Medicare & Medicaid Services.DESIGN: Comparative microsimulation modeling study using 2 independently developed models.DATA SOURCES: Derived from literature.TARGET POPULATION: A cohort of persons aged 65 years. A sensitivity analysis was also conducted, in which a cohort of persons aged 50 years was studied.TIME HORIZON: Lifetime.PERSPECTIVE: Third-party payer.INTERVENTION: Stool DNA test every 3 or 5 years in comparison with currently recommended colorectal cancer screening strategies.OUTCOME MEASURES: Life expectancy, lifetime costs, incremental cost-effectiveness ratios, and threshold costs.RESULTS OF BASE-CASE ANALYSIS: Assuming a cost of $350 per test, strategies of stool DNA testing every 3 or 5 years yielded fewer life-years and higher costs than the currently recommended colorectal cancer screening strategies. Screening with the stool DNA test would be cost-effective at a per-test cost of $40 to $60 for stool DNA testing every 3 years, depending on the simulation model used. There were no levels of sensitivity and specificity for which stool DNA testing would be cost-effective at its current cost of $350 per test. Stool DNA testing every 3 years would be cost-effective at a cost of $350 per test if the relative adherence to stool DNA testing were at least 50{\%} better than that with other screening tests.RESULTS OF SENSITIVITY ANALYSIS: None of the results changed substantially when a cohort of persons aged 50 years was considered.LIMITATION: No pathways other than the traditional adenoma-carcinoma sequence were modeled.CONCLUSION: Stool DNA testing could be a cost-effective alternative for colorectal cancer screening if the cost of the test substantially decreased or if its availability would entice a large fraction of otherwise unscreened persons to receive screening.",
keywords = "Adenoma/diagnosis, Aged, Carcinoma/diagnosis, Colorectal Neoplasms/diagnosis, Computer Simulation, Cost-Benefit Analysis, DNA, Neoplasm/analysis, Feces/chemistry, Humans, Mass Screening/economics, Medicare, Middle Aged, Reimbursement Mechanisms, Sensitivity and Specificity, United States",
author = "Iris Lansdorp-Vogelaar and Kuntz, {Karen M} and Knudsen, {Amy B} and Wilschut, {Janneke A} and Zauber, {Ann G} and {van Ballegooijen}, Marjolein",
year = "2010",
month = "9",
day = "21",
doi = "10.7326/0003-4819-153-6-201009210-00004",
language = "English",
volume = "153",
pages = "368--77",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "6",

}

Stool DNA testing to screen for colorectal cancer in the Medicare population : a cost-effectiveness analysis. / Lansdorp-Vogelaar, Iris; Kuntz, Karen M; Knudsen, Amy B; Wilschut, Janneke A; Zauber, Ann G; van Ballegooijen, Marjolein.

In: Annals of Internal Medicine, Vol. 153, No. 6, 21.09.2010, p. 368-77.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Stool DNA testing to screen for colorectal cancer in the Medicare population

T2 - a cost-effectiveness analysis

AU - Lansdorp-Vogelaar, Iris

AU - Kuntz, Karen M

AU - Knudsen, Amy B

AU - Wilschut, Janneke A

AU - Zauber, Ann G

AU - van Ballegooijen, Marjolein

PY - 2010/9/21

Y1 - 2010/9/21

N2 - BACKGROUND: The Centers for Medicare & Medicaid Services considered whether to reimburse stool DNA testing for colorectal cancer screening among Medicare enrollees.OBJECTIVE: To evaluate the conditions under which stool DNA testing could be cost-effective compared with the colorectal cancer screening tests currently reimbursed by the Centers for Medicare & Medicaid Services.DESIGN: Comparative microsimulation modeling study using 2 independently developed models.DATA SOURCES: Derived from literature.TARGET POPULATION: A cohort of persons aged 65 years. A sensitivity analysis was also conducted, in which a cohort of persons aged 50 years was studied.TIME HORIZON: Lifetime.PERSPECTIVE: Third-party payer.INTERVENTION: Stool DNA test every 3 or 5 years in comparison with currently recommended colorectal cancer screening strategies.OUTCOME MEASURES: Life expectancy, lifetime costs, incremental cost-effectiveness ratios, and threshold costs.RESULTS OF BASE-CASE ANALYSIS: Assuming a cost of $350 per test, strategies of stool DNA testing every 3 or 5 years yielded fewer life-years and higher costs than the currently recommended colorectal cancer screening strategies. Screening with the stool DNA test would be cost-effective at a per-test cost of $40 to $60 for stool DNA testing every 3 years, depending on the simulation model used. There were no levels of sensitivity and specificity for which stool DNA testing would be cost-effective at its current cost of $350 per test. Stool DNA testing every 3 years would be cost-effective at a cost of $350 per test if the relative adherence to stool DNA testing were at least 50% better than that with other screening tests.RESULTS OF SENSITIVITY ANALYSIS: None of the results changed substantially when a cohort of persons aged 50 years was considered.LIMITATION: No pathways other than the traditional adenoma-carcinoma sequence were modeled.CONCLUSION: Stool DNA testing could be a cost-effective alternative for colorectal cancer screening if the cost of the test substantially decreased or if its availability would entice a large fraction of otherwise unscreened persons to receive screening.

AB - BACKGROUND: The Centers for Medicare & Medicaid Services considered whether to reimburse stool DNA testing for colorectal cancer screening among Medicare enrollees.OBJECTIVE: To evaluate the conditions under which stool DNA testing could be cost-effective compared with the colorectal cancer screening tests currently reimbursed by the Centers for Medicare & Medicaid Services.DESIGN: Comparative microsimulation modeling study using 2 independently developed models.DATA SOURCES: Derived from literature.TARGET POPULATION: A cohort of persons aged 65 years. A sensitivity analysis was also conducted, in which a cohort of persons aged 50 years was studied.TIME HORIZON: Lifetime.PERSPECTIVE: Third-party payer.INTERVENTION: Stool DNA test every 3 or 5 years in comparison with currently recommended colorectal cancer screening strategies.OUTCOME MEASURES: Life expectancy, lifetime costs, incremental cost-effectiveness ratios, and threshold costs.RESULTS OF BASE-CASE ANALYSIS: Assuming a cost of $350 per test, strategies of stool DNA testing every 3 or 5 years yielded fewer life-years and higher costs than the currently recommended colorectal cancer screening strategies. Screening with the stool DNA test would be cost-effective at a per-test cost of $40 to $60 for stool DNA testing every 3 years, depending on the simulation model used. There were no levels of sensitivity and specificity for which stool DNA testing would be cost-effective at its current cost of $350 per test. Stool DNA testing every 3 years would be cost-effective at a cost of $350 per test if the relative adherence to stool DNA testing were at least 50% better than that with other screening tests.RESULTS OF SENSITIVITY ANALYSIS: None of the results changed substantially when a cohort of persons aged 50 years was considered.LIMITATION: No pathways other than the traditional adenoma-carcinoma sequence were modeled.CONCLUSION: Stool DNA testing could be a cost-effective alternative for colorectal cancer screening if the cost of the test substantially decreased or if its availability would entice a large fraction of otherwise unscreened persons to receive screening.

KW - Adenoma/diagnosis

KW - Aged

KW - Carcinoma/diagnosis

KW - Colorectal Neoplasms/diagnosis

KW - Computer Simulation

KW - Cost-Benefit Analysis

KW - DNA, Neoplasm/analysis

KW - Feces/chemistry

KW - Humans

KW - Mass Screening/economics

KW - Medicare

KW - Middle Aged

KW - Reimbursement Mechanisms

KW - Sensitivity and Specificity

KW - United States

U2 - 10.7326/0003-4819-153-6-201009210-00004

DO - 10.7326/0003-4819-153-6-201009210-00004

M3 - Article

VL - 153

SP - 368

EP - 377

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 6

ER -